NEC Baby Formula Lawsuits in 2026: Similac & Enfamil Claims Explained
Parents of premature babies fed Similac or Enfamil are suing the makers, claiming the formulas increased the risk of necrotizing enterocolitis (NEC), a serious intestinal disease. A $60 million Illinois verdict in March 2024 and a $495 million St. Louis verdict that July were followed by a defense verdict in November. Here is where the lawsuits stand in 2026 and who may qualify.
For visual explainers on resolving mass-tort claims, see our channel: Problem Solved.
- NEC — necrotizing enterocolitis — is a serious disease in which intestinal tissue becomes inflamed and can die; plaintiffs link it to cow's-milk-based formulas fed to premature infants.
- March 2024: an Illinois jury awarded $60 million against Mead Johnson, the maker of Enfamil, in the Watson case.
- July 2024: a St. Louis jury awarded $495 million against Abbott, the maker of Similac, in the Gill case; in November 2024 a Missouri jury returned a defense verdict for both makers in the Whitfield case.
- The federal cases are consolidated in a multidistrict litigation (MDL) in the Northern District of Illinois, with about 663 cases pending as of March 2025 and bellwether trials scheduled from 2025 into 2026.
1. What Is NEC and Why Formula Is Blamed
Necrotizing enterocolitis, or NEC, is a disease in which a newborn's intestinal tissue becomes inflamed and can begin to die, sometimes requiring emergency surgery. It strikes premature infants far more often than full-term babies. The lawsuits allege that cow's-milk-based formulas — including Similac and Enfamil — raise NEC risk in preterm babies versus breast milk, and that manufacturers knew of the risk yet failed to warn parents and hospitals.
The companies dispute this. Their position, argued in court, is that the science does not prove their products cause NEC and that formula remains an essential nutrition source when breastfeeding is not possible. This clash — plaintiff science versus defense science — is why the litigation has produced both enormous verdicts and a defense verdict within the same year.
2. The $60 Million Watson Verdict (March 2024)
The first major bellwether-style test came in March 2024, when an Illinois state jury awarded $60 million to the family of Jasmine Watson, a premature baby who developed NEC after being fed Enfamil products. The jury found against Mead Johnson, Enfamil's maker. The award included both compensatory and punitive damages, and it signaled to the industry that juries were willing to hold formula makers accountable.
3. The $495 Million Gill Verdict (July 2024)
Four months later, a St. Louis jury went much further. In the case of Margo Gill, the jury awarded $495 million against Abbott Laboratories, the maker of Similac, finding that its cow's-milk-based products contributed to the child's NEC. It remains one of the largest verdicts of its kind — and it dramatically raised the stakes for every case still waiting in the federal docket.
4. The Whitfield Defense Verdict (November 2024)
Then came the counterweight. In November 2024, a Missouri jury in the Whitfield case returned a defense verdict for both Abbott and Mead Johnson, rejecting the plaintiffs' claims. The result proved something important for families to understand: these cases are genuinely contested, outcomes vary sharply from trial to trial, and no result in one courtroom guarantees the result in another.
5. The Federal MDL and Where Cases Stand
A multidistrict litigation — MDL — is a procedure that gathers similar federal lawsuits before one judge for pretrial proceedings, keeping the science and evidence consistent across hundreds of cases. The NEC formula cases are consolidated in the Northern District of Illinois. As of March 2025, about 663 cases were pending there, and bellwether trials — early test trials whose results guide settlement talks — are scheduled from 2025 into 2026.
Mass-tort litigation follows familiar patterns across product categories. Readers tracking other large litigations may recognize the same structure in asbestos claims or AFFF firefighting-foam claims, where consolidation, bellwethers, and then settlement negotiations set the rhythm of the docket.
6. Who May Qualify to File a Claim
Generally, the claims involve a premature infant who was fed a cow's-milk-based formula — Similac or Enfamil — and then diagnosed with NEC. Each case turns on its own medical records, the timing of feeding and diagnosis, and the severity of the outcome. Statutes of limitations — the legal deadlines for filing — differ by state and can be strict, so families who believe they were affected should speak with a qualified attorney promptly rather than waiting to see how the MDL resolves.
7. What Families Should Know About Compensation
The honest answer about money: compensation varies widely by case and most settlements are confidential. The only public figures are the documented verdicts — $60 million in Watson, $495 million in Gill — plus the defense verdict in Whitfield, which paid nothing. Large verdicts also face appeals and reductions, so a headline number is not a promise of what any individual family will receive.
What drives value in an individual case is the strength of the medical evidence, the severity of the injury, and the quality of the records — not verdicts in other courtrooms. Be skeptical of any advertisement promising a specific payout; ethical attorneys evaluate cases individually and never guarantee results.
8. Next Steps If Your Family Was Affected
Start by gathering records: hospital and NICU files, the specific formula products used, dates of feeding and diagnosis, and communications with medical providers. Write down a timeline while memories are fresh. Then consult a licensed attorney experienced in mass-tort litigation — most offer free case reviews and work on contingency, meaning no upfront legal fees.
Who Benefits From This — and Who Does Not
NEC formula claims turn on medical records, timing, and deadlines — not on verdict headlines from other families' cases.
Who benefits:
- Families of a premature infant fed a cow's-milk-based Similac or Enfamil formula who was then diagnosed with NEC: Start by gathering hospital and NICU files, the specific formula products used, dates of feeding and diagnosis, and communications with providers, then have a qualified attorney review the records.
- Families with a clear timeline and strong records: What drives value in an individual case is the strength of the medical evidence, the severity of the injury, and the quality of the records — so a written timeline made while memories are fresh is the most useful first step.
- Families unsure whether they still have time: Deadlines differ by state and by case and can be strict, and about 663 cases were pending in the federal multidistrict litigation in the Northern District of Illinois as of March 2025 — prompt review protects your options.
Who benefits little or nothing:
- Families outside the claim pattern: The claims generally involve a premature infant fed a cow's-milk-based formula who developed NEC — without that combination, this litigation is unlikely to apply.
- Anyone expecting a fixed payout from verdict headlines: The public figures are other cases' outcomes — $60 million in Watson, $495 million in Gill — and a defense verdict in Whitfield; compensation varies widely by case and most settlements are confidential.
- Anyone relying on advertisements promising an outcome: Be skeptical of any advertisement promising a result — the makers dispute that the science proves causation, and each case turns on its own records.
Related reading: AFFF Lawyer 2026: Firefighting Foam Lawsuits, Settlements & How to File
Frequently Asked Questions
What are the NEC baby formula lawsuits about?
Parents allege that Similac and Enfamil cow's-milk-based formulas raised the risk of necrotizing enterocolitis — a serious intestinal disease — in premature babies, and that the makers failed to warn families and hospitals. The companies dispute the claims and have won at least one trial.
How much have juries awarded in NEC formula cases?
A March 2024 Illinois jury awarded $60 million against Mead Johnson, the maker of Enfamil, in the Watson case. A July 2024 St. Louis jury awarded $495 million against Abbott, the maker of Similac, in the Gill case. A November 2024 Missouri jury returned a defense verdict for both makers in the Whitfield case. Compensation varies widely by case and most settlements are confidential.
How many NEC lawsuits are currently pending?
About 663 cases were pending in the federal multidistrict litigation in the Northern District of Illinois as of March 2025, with bellwether trials scheduled from 2025 into 2026.
Can I still file a NEC lawsuit in 2026?
Possibly. Deadlines known as statutes of limitations differ by state and by case, and they can be strict. A qualified attorney can review your family's records and tell you whether you qualify and how much time you have.
Who may qualify to bring an NEC formula claim?
Generally, families of a premature infant who was fed a cow's-milk-based Similac or Enfamil formula and then diagnosed with NEC — each case turns on its own medical records, the timing of feeding and diagnosis, and the applicable state deadline.
Who should not expect a payout from NEC verdict headlines?
Anyone treating other cases' verdicts — $60 million in Watson, $495 million in Gill — as a promise: Whitfield ended in a defense verdict, compensation varies widely by case, and most settlements are confidential.
General educational information — not legal advice. Consult a licensed professional for your situation.